These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32210973)

  • 1. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.
    Miller SM; Cybulski V; Whitacre M; Bess LS; Livesay MT; Walsh L; Burkhart D; Bazin HG; Evans JT
    Front Immunol; 2020; 11():406. PubMed ID: 32210973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
    Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
    Front Immunol; 2018; 9():2619. PubMed ID: 30515151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
    Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
    Front Immunol; 2020; 11():1207. PubMed ID: 32636840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Nishiyama A; Adachi Y; Tonouchi K; Moriyama S; Sun L; Aoki M; Asanuma H; Shirakura M; Fukushima A; Yamamoto T; Takahashi Y
    Vaccine; 2023 Jul; 41(31):4525-4533. PubMed ID: 37330368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
    Jangra S; De Vrieze J; Choi A; Rathnasinghe R; Laghlali G; Uvyn A; Van Herck S; Nuhn L; Deswarte K; Zhong Z; Sanders NN; Lienenklaus S; David SA; Strohmeier S; Amanat F; Krammer F; Hammad H; Lambrecht BN; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9467-9473. PubMed ID: 33464672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
    Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
    Front Immunol; 2018; 9():295. PubMed ID: 29515589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
    Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
    J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice.
    Jangra S; Lamoot A; Singh G; Laghlali G; Chen Y; Ye T; García-Sastre A; De Geest BG; Schotsaert M
    Front Immunol; 2024; 15():1370564. PubMed ID: 38711520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
    Misiak A; Leuzzi R; Allen AC; Galletti B; Baudner BC; D'Oro U; O'Hagan DT; Pizza M; Seubert A; Mills KHG
    Vaccine; 2017 Sep; 35(39):5256-5263. PubMed ID: 28823618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.